Disease Domain | Count |
---|---|
Neoplasms | 2 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Therapeutic radiopharmaceuticals | 1 |
Diagnostic radiopharmaceuticals | 1 |
Mechanism EGFR antagonists [+1] |
Active Org.- |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CTNNB1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FAP modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date26 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Y-90 Resin Microspheres | Hepatocellular Carcinoma More | Phase 2 |
PRN-371 ( JAK3 ) | T-Cell Lymphoma More | Preclinical |
18F-RO-7016970 ( FAP ) | Pulmonary Fibrosis More | Preclinical |
GB-1874 ( CTNNB1 ) | Colorectal Cancer More | Preclinical |
Triptolide ( EGFR x HSP70 heat-shock proteins ) | Breast Cancer More | Discontinued |